Ishii M, Urabe T, Seino Y
Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 1):1860-5.
The clinical usefulness of DU-PAN-2 as a tumor marker was investigated. DU-PAN-2 antigen was detected by enzyme immunoassay based on sandwiching the antigen between monoclonal antibodies to DU-PAN-2. The EIA kit was supplied from Kyowa Medex Co. The mean DU-PAN-2 concentration in sera from 53 healthy donors was 51.8 U/ml and the mean plus 2 S.D. value was 156.2 U/ml. A level of 160 U/ml was used as the cut-off value. Serum DU-PAN-2 was positive in 7.5% of healthy donors, 16.9% of 83 patients with benign disease and 37.7% of 159 cancer patients. Of the cancer patients, those with pancreatic cancer, bile duct cancer and primary liver cell cancer had a high positive frequency of more than 70%. On the other hand, of patients with benign diseases, a high positive incidence of 40% or 50% was observed in patients with chronic hepatitis or liver cirrhosis. From this result, DU-PAN-2 appeared to be useful as a tumor for pancreatic cancer and bile duct cancer. Determination of the molecular weight of DU-PAN-2 in serum from a pancreatic cancer patient by Sepharose 4B gel filtration demonstrated the existence as a high-molecular-weight protein between about M.W. 500-10,000 K Da.
对DU-PAN-2作为一种肿瘤标志物的临床实用性进行了研究。基于将抗原夹在针对DU-PAN-2的单克隆抗体之间，通过酶免疫测定法检测DU-PAN-2抗原。酶免疫测定试剂盒由协和梅迪克公司提供。53名健康供者血清中DU-PAN-2的平均浓度为51.8 U/ml，平均加2个标准差的值为156.2 U/ml。以160 U/ml作为临界值。健康供者中7.5%的人血清DU-PAN-2呈阳性，83例良性疾病患者中有16.9%呈阳性，159例癌症患者中有37.7%呈阳性。在癌症患者中，胰腺癌、胆管癌和原发性肝细胞癌患者的阳性频率较高，超过70%。另一方面，在良性疾病患者中，慢性肝炎或肝硬化患者的阳性发生率较高，为40%或50%。根据这一结果，DU-PAN-2似乎对胰腺癌和胆管癌作为一种肿瘤标志物是有用的。通过琼脂糖4B凝胶过滤法测定一名胰腺癌患者血清中DU-PAN-2的分子量，结果表明其以分子量约为500-10,000 kDa的高分子量蛋白形式存在。
